Back to results
US 2023/0271965 A1Published application
Bicyclic heteroarenes and methods of their use
AssigneeKineta, Inc.
InventorsKerem OZBOYA, Iwona WRONA, Bertrand LE BOURDONNEC, Matthew LUCAS, Vanessa KURIA, Madeline MACDONNELL, Byron DELABARRE
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
Claims66
A compound of formula (I):
- or a pharmaceutically acceptable salt thereof,
- wherein
- is a single bond, X1 is (C(RA)2)m or —OC(RA)2—RX, and X2 is C(RA)2 or CO;
- is a double bond, and each of X1 and X2 is independently CRA or N, wherein RX is a bond to X2;
- R1 is -(L)n-R1;
- optionally substituted C1-9 alkoxy;
- optionally substituted C1-9 heterocyclyl comprising at least one endocyclic oxygen;
- unsubstituted pyrimidinyl;
- optionally substituted pyridazinyl;
- optionally substituted oxazolyl, or pyrid-2-on-1-yl;
- R2 is optionally substituted C6-10 aryl, optionally substituted C1-9 heterocyclyl, or optionally substituted C1-9 heteroaryl;
- R3 is a group of the following structure:
- each RA is independently H, optionally substituted C1-6 alkyl, or optionally substituted C6-10 aryl;
- RB is optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl;
- RC is H or optionally substituted C1-6 alkyl;
- each L is independently optionally substituted C1-6 alkylene, O, or NRC;
- n is 1, 2, or 3;
- and
- m is 0, 1, or 2.
16 more elements
A compound of the following structure:
- or a pharmaceutically acceptable salt thereof.
A compound of the following structure:
- or a pharmaceutically acceptable salt thereof.
A method of treating a TDP-43-associated disorder in a subject, the method comprising administering to the subject in need thereof an effective amount of the compound of formula (I):
- or a pharmaceutically acceptable salt thereof,
- wherein
- is a single bond, X1 is (C(RA)2)m or —OC(RA)2—RX, and X2 is C(RA)2 or CO;
- or is a double bond, and each of X1 and X2 is independently CRA or N, wherein RX is a bond to X2;
- R1 is -(L)n-RB;
- hydrogen;
- halogen;
- cyano;
- optionally substituted C1-6 alkyl;
- optionally substituted C1-6 heteroalkyl;
- optionally substituted C1-6 alkoxy;
- optionally substituted C6-10 aryl, optionally substituted C1-9 heterocyclyl, or optionally substituted C1-9 heteroaryl;
- R2 is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heterocyclyl, or optionally substituted C1-9 heteroaryl;
- R3 is a group of the following structure:
- each RA is independently H, optionally substituted C1-6 alkyl, or optionally substituted C6-10 aryl;
- RB is optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl;
- RC is H or optionally substituted C1-6 alkyl;
- each L is independently optionally substituted alkylene, O, or NRC;
- and
- n is 1, 2, or 3;
- and
- m is 0, 1, or 2.
19 more elements
Dependencies are inferred from the claim text.